{
    "clinical_study": {
        "@rank": "164779", 
        "arm_group": [
            {
                "arm_group_label": "Biweekly cetuximab with continuously FOLFIRI", 
                "arm_group_type": "Active Comparator", 
                "description": "Biweekly cetuximab 500 mg/m2 in combination with FOLFIRI (irinotecan 180 mg/m2 IV, leucovorin: 400 mg/m2 IV, 5FU bolus: 400 mg/m2 IV and 46 hours 5FU infusion of 2400 mg/m2 every 2 weeks)"
            }, 
            {
                "arm_group_label": "Biweekly cetuximab with alternating FOLFIRI and mFOLFOX6", 
                "arm_group_type": "Experimental", 
                "description": "Biweekly cetuximab 500 mg/m2 in combination with FOLFIRI alternating with FOLFOX6 (Oxaliplatin: 85 mg/m2 IV, leucovorin: 400 mg/m2 IV, 5FU bolus: 400 mg/m2 IV and 46 hours 5FU infusion of 2400 mg/m2 every 2 weeks)"
            }
        ], 
        "brief_summary": {
            "textblock": "Nordic randomized phase II trial which evaluates whether biweekly cetuximab with alternating\n      FOLFIRI and mFOLFOX6 is more effective than biweekly cetuximab with continuously FOLFIRI in\n      patients with potential resectable KRAS wildtype metastatic colorectal cancer.\n\n      All patients will be randomized to biweekly cetuximab 500 mg/m2 in combination with arm A)\n      FOLFIRI (irinotecan 180 mg/m2 IV, leucovorin: 400 mg/m2 IV, 5FU bolus: 400 mg/m2 IV and 46\n      hours 5FU infusion of 2400 mg/m2 every 2 weeks) or arm B) FOLFIRI alternating with FOLFOX6\n      (Oxaliplatin: 85 mg/m2 IV, leucovorin: 400 mg/m2 IV, 5FU bolus: 400 mg/m2 IV and 46 hours\n      5FU infusion of 2400 mg/m2 every 2 weeks) .\n\n      Primary objective: response rate (RECIST 1.1) in patients with with potential resectable\n      KRAS wildtype metastatic colorectal cancer.\n\n      Secondary objectives: Resection rate, PFS, OS, Quality of life, tolerability. Biomarker\n      evaluation to measure plasma biomarkers, Tumour blocks and sequential serum and plasma will\n      be collected to  search for markers that may predict efficacy including respectability and\n      safety."
        }, 
        "brief_title": "Nordic 8 - A Phase II Trial", 
        "condition": "Metastatic Colorectal Cancer", 
        "condition_browse": {
            "mesh_term": "Colorectal Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Histology and stages:\n\n          -  Histologically proven adenocarcinoma in the colon or rectum\n\n          -  At least 1 measurable metastatic disease manifestation according to the RECIST\n             criteria (version 1.1)\n\n          -  Potentially completely resectable or potentially curable metastatic colorectal cancer\n             as determined by the local MDT conference and that requires tumour shrinkage before\n             resection is possible. The following definitions are indicative:\n\n               -  4 or more liver metastases (CRLeM) without extra-hepatic disease\n\n               -  2 or more lung metastases (CRLuM) without hepatic or extra-hepatic disease\n\n               -  1 or more CRLeM determined as \"potentially resectable\" (such as because of\n                  location) by the local MDT.\n\n               -  1 or more CRLuM determined by the local MDT as potentially resectable (such as\n                  because of location).\n\n               -  Non-resectable primary disease with resectable CRLeM or CRLuM.\n\n        KRAS and BRAF status:\n\n        - Tumour tissue (primary or metastasis) typed as wild-type KRAS AND wild-type BRAF\n\n        General conditions:\n\n          -  age > 18 years\n\n          -  WHO performance status \u2264 1\n\n          -  expected survival > 3 months\n\n          -  sufficient bone-marrow function (Hb \u2265 6.2 \u00b5mol/l/Hb > 10 g/dl ANC \u2265 1.5 x 109/l,\n             thrombocytes \u2265 100 x 109/l)\n\n          -  sufficient kidney and liver function: total bilirubin \u2264 1.5 x upper normal limit,\n             serum creatinine \u2264 1.25 x upper normal limit, ALAT \u2264 3 x upper normal limit and \u2264 5 x\n             upper normal limit with liver metastases\n\n          -  the patient must have signed an informed declaration of consent before being\n             registered; this must be documentable according to national guidelines\n\n        Exclusion Criteria:\n\n        Previous treatment:\n\n          -  previous chemotherapy for advanced/metastatic disease\n\n          -  adjuvant chemotherapy unless completed more than 6 months before registration\n\n          -  previous treatment with oxaliplatin or irinotecan\n\n          -  previous treatment with cetuximab or other treatment for EGFR\n\n          -  History of Inflammatory Bowel disease\n\n          -  Severe or uncontrolled cardiovascular disease, congestive heart failure NYHA III or\n             IV, unstable angina pectoris, history of myocardial infarction within the last twelve\n             months, significant arrhythmias)\n\n          -  Any condition that, according to the treating physician's judgement, could prevent\n             the planned medical/surgical treatment from being carried out responsibly (such as\n             uncontrolled active infection, known hypersensitivity or contra-indication for the\n             planned treatment.\n\n          -  Pregnant or breast-feeding women\n\n          -  Patients of fertile age who do not want to use reliable contraception"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "180", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 21, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01867697", 
            "org_study_id": "Nordic 8"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Biweekly cetuximab with continuously FOLFIRI", 
                    "Biweekly cetuximab with alternating FOLFIRI and mFOLFOX6"
                ], 
                "intervention_name": "Cetuximab", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Biweekly cetuximab with continuously FOLFIRI", 
                    "Biweekly cetuximab with alternating FOLFIRI and mFOLFOX6"
                ], 
                "intervention_name": "Irinotecan", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Biweekly cetuximab with alternating FOLFIRI and mFOLFOX6", 
                "intervention_name": "Oxaliplatin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Biweekly cetuximab with continuously FOLFIRI", 
                    "Biweekly cetuximab with alternating FOLFIRI and mFOLFOX6"
                ], 
                "intervention_name": "Folinic Acid", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Biweekly cetuximab with continuously FOLFIRI", 
                    "Biweekly cetuximab with alternating FOLFIRI and mFOLFOX6"
                ], 
                "intervention_name": "Calcium Carbonate", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Calcium Carbonate", 
                "Leucovorin", 
                "Folic Acid", 
                "Levoleucovorin", 
                "Oxaliplatin", 
                "Irinotecan", 
                "Cetuximab"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "June 3, 2013", 
        "location": [
            {
                "contact": {
                    "email": "m.yilmaz@rn.dk", 
                    "last_name": "Mette Yilmaz, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Aalborg", 
                        "country": "Denmark", 
                        "zip": "9100"
                    }, 
                    "name": "Aalborg University Hospital"
                }, 
                "investigator": {
                    "last_name": "Mette Yilmaz, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Flemming Hansen, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Aarhus", 
                        "country": "Denmark", 
                        "zip": "8000"
                    }, 
                    "name": "Aarhus University Hospital"
                }, 
                "investigator": {
                    "last_name": "Flemming Hansen, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "lone.noergaard.petersen@rh.regionh.dk", 
                    "last_name": "Lone Noergaard, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Copenhagen", 
                        "country": "Denmark", 
                        "zip": "2100"
                    }, 
                    "name": "Rigshospitalet"
                }, 
                "investigator": [
                    {
                        "last_name": "Lone Noergaard, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Peter Noerregaard, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "Brita.Bjerregaard.Jensen@svs.regionsyddanmark.dk", 
                    "last_name": "Brita Bjerregaard, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Esbjerg", 
                        "country": "Denmark", 
                        "zip": "6700"
                    }, 
                    "name": "Sydvestjysk Hospital"
                }, 
                "investigator": {
                    "last_name": "Brita Bjerregaard, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "'BEVI@heh.regionh.dk'", 
                    "last_name": "Benny V Jensen, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Herlev", 
                        "country": "Denmark", 
                        "zip": "2730"
                    }, 
                    "name": "Herlev University Hospital"
                }, 
                "investigator": {
                    "last_name": "Benny V Jensen, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "nina.keldsen@vest.rm.dk", 
                    "last_name": "Nina Keldsen, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Herning", 
                        "country": "Denmark"
                    }, 
                    "name": "Herning Hospital"
                }, 
                "investigator": {
                    "last_name": "Nina Keldsen, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "nhho@regionsjaelland.dk", 
                    "last_name": "Niels Holl\u00e4nder, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Naestved", 
                        "country": "Denmark", 
                        "zip": "4700"
                    }, 
                    "name": "Naestved Hospital"
                }, 
                "investigator": {
                    "last_name": "Niels Holl\u00e4nder, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "per.pfeiffer@ouh.regionsyddanmark.dk", 
                    "last_name": "Per Pfeiffer, Professor", 
                    "phone": "+45 6541 1590"
                }, 
                "contact_backup": {
                    "email": "camilla.qvortrup@ouh.regionsyddanmark.dk", 
                    "last_name": "Camilla Qvortrup, MD, PhD", 
                    "phone": "+45 6541 4852"
                }, 
                "facility": {
                    "address": {
                        "city": "Odense", 
                        "country": "Denmark", 
                        "zip": "5000"
                    }, 
                    "name": "Odense University Hospital"
                }, 
                "investigator": [
                    {
                        "last_name": "Per Pfeiffer, Professor", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Camilla Qvortrup, MD, PhD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Henning Overgaard, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "jsla@regionsjaelland.dk", 
                    "last_name": "Jim Larsen, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Roskilde", 
                        "country": "Denmark", 
                        "zip": "4000"
                    }, 
                    "name": "Roskilde Hospital"
                }, 
                "investigator": {
                    "last_name": "Jim Larsen, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "halfdan.sorbye@helse-bergen.no", 
                    "last_name": "Halfdan S\u00f8rbye, Professor"
                }, 
                "facility": {
                    "address": {
                        "city": "Bergen", 
                        "country": "Norway", 
                        "zip": "5021"
                    }, 
                    "name": "Haukeland University Hospital"
                }, 
                "investigator": {
                    "last_name": "Halfdan S\u00f8rbye, Professor", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "Eva.Hofsli@stolav.no", 
                    "last_name": "Eva Hofsli, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Trondheim", 
                        "country": "Norway"
                    }, 
                    "name": "Trondheim University Hospital"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "bengt.glimelius@onkologi.uu.se", 
                    "last_name": "Bengt Glimelius, Professor"
                }, 
                "facility": {
                    "address": {
                        "city": "Uppsala", 
                        "country": "Sweden", 
                        "zip": "751 85"
                    }, 
                    "name": "Akademiska University Hospital"
                }, 
                "investigator": {
                    "last_name": "Bengt Glimelius, Professor", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Denmark", 
                "Norway", 
                "Sweden"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "Potentially Resectable Metastatic Colorectal Cancer With Wild-type KRAS and BRAF: Alternating Chemotherapy Plus Cetuximab - A Randomised Phase II Trial", 
        "overall_contact": {
            "email": "per.pfeiffer@ouh.regionsyddanmark.dk", 
            "last_name": "Per Pfeiffer, Professor", 
            "phone": "+45 6541 1590"
        }, 
        "overall_contact_backup": {
            "last_name": "Camilla Qvortrup, MD, PhD", 
            "phone": "+45 6541 4852"
        }, 
        "overall_official": [
            {
                "affiliation": "Odense University Hospital", 
                "last_name": "Per Pfeiffer, Professor, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Haukeland University Hospital", 
                "last_name": "Halfdan S\u00f8rbye, Professor, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Akademiske Sygehus, Uppsala University", 
                "last_name": "Bengt Glimelius, Professor, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Denmark: Danish Dataprotection Agency", 
                "Denmark: Ethics Committee"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Response rate (RR)", 
            "safety_issue": "Yes", 
            "time_frame": "March 2015 (up to 3 years)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01867697"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Odense University Hospital", 
            "investigator_full_name": "Per Pfeiffer", 
            "investigator_title": "Professor, MD, PhD", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Survival (Overall survival)", 
                "safety_issue": "No", 
                "time_frame": "June 2016 (up to 5 years)"
            }, 
            {
                "measure": "Frequency of secondary surgical resection (R0 + R1 + R2 resections)", 
                "safety_issue": "No", 
                "time_frame": "January 2015 (up to 3 years)"
            }, 
            {
                "measure": "Frequency of secondary micro-radical surgical resection (R0 resection)", 
                "safety_issue": "No", 
                "time_frame": "March 2015 (up to 3 years)"
            }
        ], 
        "source": "Odense University Hospital", 
        "sponsors": {
            "collaborator": {
                "agency": "Merck Serono International SA", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Per Pfeiffer", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}